ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia.

MLA

Eichhorst, B., et al. “ESMO Clinical Practice Guideline Interim Update on New Targeted Therapies in the First Line and at Relapse of Chronic Lymphocytic Leukaemia.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 35, no. 9, Sept. 2024, pp. 762–68. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.06.016.

APA

Eichhorst, B., Ghia, P., Niemann, C. U., Kater, A. P., Gregor, M., Hallek, M., Jerkeman, M., & Buske, C. (2024). ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 35(9), 762–768. https://doi.org/10.1016/j.annonc.2024.06.016

Chicago

Eichhorst, B, P Ghia, C U Niemann, A P Kater, M Gregor, M Hallek, M Jerkeman, and C Buske. 2024. “ESMO Clinical Practice Guideline Interim Update on New Targeted Therapies in the First Line and at Relapse of Chronic Lymphocytic Leukaemia.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 35 (9): 762–68. doi:10.1016/j.annonc.2024.06.016.